drugset / Trial / NCT05849558

Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

NCT05849558

Phase 4 Unknown 297 enrolled MinaPharm Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients

Timeline

Start
2022-02-22
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Silymarin Traditional medicine (herbal / TCM) 140 mg
Comparator Ursodeoxycholic Acid Small molecule 250 mg

Indications